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Background: Several studies have identified use of non-steroidal-anti-inflammatory drugs and statins for prevention
of dementia, but their efficacy in slowing progression is not well understood. Cerebrovascular disturbances are
common pathological feature of Alzheimer’s disease. We previously reported chronic ingestion of saturated fatty
acids (SFA) compromises blood–brain barrier (BBB) integrity resulting in cerebral extravasation of plasma proteins
and inflammation. However, the SFA-induced parenchymal accumulation of plasma proteins could be prevented by
co-administration of some cholesterol lowering agents. Restoration of BBB dysfunction is clinically relevant, so the
purpose of this study was to explore lipid-lowering agents could reverse BBB disturbances induced by chronic
ingestion of SFA’s.
Methods: Wild-type mice were fed an SFA diet for 12 weeks to induce BBB dysfunction, and then randomised to
receive atorvastatin, pravastatin or ibuprofen in combination with the SFA-rich diet for 2 or 8 weeks. Abundance of
plasma-derived immunoglobulin-G (IgG) and amyloid-β enriched apolipoprotein (apo)-B lipoproteins within brain
parenchyme were quantified utilising immunofluorescence microscopy.
Results: Atorvastatin treatment for 2 and 8 weeks restored BBB integrity, indicated by a substantial reduction of IgG
and apo B, particularly within the hippocampus. Pravastatin, a water-soluble statin was less effective than
atorvastatin (lipid-soluble). Statin effects were independent of changes in plasma lipid homeostasis. Ibuprofen, a
lipid-soluble cyclooxygenase inhibitor attenuated cerebral accumulation of IgG and apo B as effectively as
atorvastatin. Our findings are consistent with the drug effects being independent of plasma lipid homeostasis.
Conclusion: Our findings suggest that BBB dysfunction induced by chronic ingestion of SFA is reversible with
timely introduction and sustained treatment with agents that suppress inflammation.
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Accumulating evidence is consistent with the concept
that the onset and progression of Alzheimer’s disease
(AD) is influenced by vascular-risk factors. A number of
studies have demonstrated a positive association
between AD and atherosclerosis, cardiovascular disease,
dyslipidaemia, hypertension and insulin resistance [1,2].* Correspondence: J.Mamo@curtin.edu.au
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distribution, and reproduction in any mediumPopulation studies have also demonstrated that con-
sumption of diets which compromise vascular integrity,
such as those enriched in saturated-fatty acids, trans-
fatty acids, or cholesterol are also associated with
increased risk of AD [3-5]. Moreover, recent animal
model and clinical studies suggest that cerebral capillary
dysfunction may develop with ageing in the absence of
other significant comorbidities [6-8]. Clearly, identifying
strategies to prevent or regress this age-induced effect
on cerebrovascular function is a therapeutic priority
given the aging population of developed and developing
countries.BioMed Central Ltd. This is an Open Access article distributed under the terms of
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dysfunction precedes amyloidosis, a hallmark patho-
logical protein marker for Alzheimer’s disease [9]. Com-
mon vascular pathological alterations prior to amyloid
deposition include a reduction of cerebral capillary
endothelial tight junction proteins and increased endo-
thelial pinocytic activity, which in combination result in
parenchymal extravasation of plasma proteins within
brain parenchyma [10-13]. Activation of glial cells and
mitochondrial respiration are markedly increased, alter-
ing the phenotypic properties of astrocytes. In response
to cytokine production by the latter, parenchymal pene-
trance of circulating monocytes may subsequently occur
[10]. Thereafter, deposition of extracellular proteogly-
cans and collagen reduce arterial distensibility and may
cause gross convolutional abnormalities including total
capillary collapse with significant alterations in brain
blood perfusion [14,15].
Several lines of evidence are consistent with the
hypothesis that suppressing cerebral capillary inflamma-
tion may confer benefit to AD onset, or disease progres-
sion. Reducing the plasma concentration of cytokines
and pro-inflammatory proteins by the regular consump-
tion of foods or vitamin supplements that suppress in-
flammation is associated with a delay for development of
dementia [16-19]. Furthermore, attenuation of cere-
bral capillary inflammatory processes by inhibition of
cyclooxygenase (COX) via the use of non-steroidal anti-
inflammatory drugs (NSAIDs) may aid in prevention
and treatment of AD. Although beneficial properties of
NSAIDs in prevention of AD remain controversial [20],
some human epidemiological studies suggest that long-
term uses of NSAIDs are protective against AD [21].
The adjusted odds ratios (OR) for AD among NSAID
users decreased from 0.98 for less than or equal to one
year of use, to 0.76 for greater than five years of use
[21]. For users of ibuprofen, the OR decreased substan-
tially from 1.03 to 0.56. In a primary prevention study
(ADAPT trial) of naproxen (a non-selective COX inhibi-
tor) and celecoxib (a COX-2 selective inhibitor), a 4-year
follow-up assessment revealed that subjects previously
exposed to naproxen were protected from the onset of
AD by 67% compared to placebo [22]. Further analysis
of the study identified reduced AD incidence in asymp-
tomatic individuals. However, there were adverse effects
at later stages of AD [23]. Therefore, it could be hypothe-
sised that the chronic use of selected and non-specific
NSAIDs may be beneficial in the early stages of AD. Direct
evidence of an early preventive effect comes from animal
studies, which have shown that a range of both COX-1
and COX-2 inhibitors can reduce plaque burden in AD
mice and improve cognition in others [24,25].
Population studies also support a role for anti-
inflammatory lipid lowering agents in the prevention ofdementia. The 3-City Study represents a cohort of more
than 9,000 subjects examining the association of plasma
cholesterol and lipid-lowering agent intake with demen-
tia prevalence [26]. In that cohort, 2% of participants
were demented at baseline. Of the remainder, 30% of the
subjects had been prescribed either HMGCoA reductase
inhibitors (statins) or peroxisome proliferator activated
receptor agonists (fibrates). The HMGCoA reductase
inhibitors are widely used lipid-lowering agents that
effectively reduce cardiovascular disease risk by not only
a reduction in plasma cholesterol, but additionally pleio-
tropic anti-inflammatory properties. The study observed
the OR for dementia was significantly lower among
users of lipid lowering agents (OR = 0.61) compared with
subjects taking no lipid lowering agents; the effect was
similar between statin and fibrate users. The odds for
dementia were increased in subjects with hyperlipidemia
that were not treated with statins (OR = 1.43). This
particular observational study suggests that anti-
inflammatory lipid lowering agents could be associated
with decreased risk of dementia. However, following
adjusting for multiple co-founders, no association was
found between lipid lowering agent intake in late life
and reduced risk of dementia [27].
Presently, there is insufficient evidence to recommend
statins for the treatment of dementia once disease is
established or advanced [28]. However, in a cohort of ap-
proximately 3,100 subjects, the adjusted hazards ratio
for developing AD was substantially reduced in subjects
who commenced statin therapy at an earlier age [29].
This finding may explain paradoxical clinical studies,
with only some statin interventions demonstrating bene-
fit in subjects with AD [30,31]. Interestingly, a study in
normolipemic spontaneously hypertensive rats supports
the notion that statins have beneficial cerebral capillary
effects; where atorvastatin was shown to prevent blood–
brain barrier (BBB) dysfunction [32]. In culture studies
of rat brain endothelial cells, pitavastatin was reported
to strengthen the BBB integrity [33].
In a clinical context restoration of cerebral capillary
integrity would be therapeutically beneficial for slowing
or delaying AD progression, although presently this is a
difficult phenomenon to assess in vivo. Despite this diffi-
culty, proof-of-concept data using surrogate markers of
cerebrovascular inflammation in relevant animal models
would provide information on the putative efficacy of
selected and targeted interventions. Our preliminary
investigations demonstrated beneficial effects of atorvas-
tatin in preventing saturated-fatty-acid (SFA) induced
cerebrovascular dysfunction [34]. However, restoration
by anti-inflammatory agents of BBB function has not
been previously investigated. In this study, following,
dietary SFA-induced disturbances of BBB integrity, mice
were randomised to receive atorvastatin, pravastatin, or
Figure 1 Quantition of cerebral IgG and apo B in mice
randomised to drug diets for 2 weeks. The bar graphs show 3-
dimensional (3D) quantitative analysis of IgG (frame A) and apo B
(frame B) leakage of wild-type mouse brains at 2 weeks of drug
consumption. Pixel intensity of IgG and apo B was quantitated
surrounding the cerebrovasculature in mice fed low-fat (LF),
saturated-fatty acids (SFA) and SFA mice randomised to diets
containing atorvastatin (LF + At, SFA + At), pravastatin (LF + Pr, SFA +
Pr) and ibuprofen (LF + Ib, SFA + Ib). Immunoglobulin-G and apo B
pixel intensity was measured in the cortex (CTX, black column),
brain-stem (BS, white column) and hippocampal formation (HPF,
dotted column) and expressed as per unit volume. Symbol→
indicate that mice were fed SFA diet for 12 weeks and then the diet
was replaced (→) with a drug containing diet. The bars represent
mean intensity and standard error of mean, where P < 0.05
considered statistically significant. a: statistically significant in
comparison to LF. b: statistically significant in comparison to SFA.
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molecular weight plasma proteins, including apolipopro-
tein (apo)-B lipoproteins that are endogenously enriched
in amyloid-β (Aβ) was assessed.
Results
Our results confirm the significant abundance of
immunoglobulin-G (IgG) and distribution within the cor-
tex (CTX), brainstem (BS) and hippocampal formation
(HPF) in SFA fed wild-type (WT) (Figure 1 and Figure 2).
The SFA fed mice had a five-fold greater abundance of
IgG compared to the low fat (LF)-control mice, with the
majority of this accumulation being indicated within the
CTX >HPF > BS. However, HPF had the largest increase
in IgG as a consequence of SFA feeding compared to the
LF-control fed mice. Following SFA feeding for 12 weeks,
provision of atorvastatin, pravastatin or ibuprofen for
2 weeks generally reduced the total parenchymal IgG
abundance, however there were differential effects of the
agents with respect to efficacy and tissue distribution. The
abundance of IgG was essentially completely reversed with
atorvastatin, a lipid soluble drug and notably, completely
ameliorated the HPF accumulation. In contrast, the IgG
distribution in mice given water-soluble pravastatin was
not significantly different compared to the SFA treated
group. Ibuprofen attenuated IgG as effectively as mice
provided with atorvastatin. There was no statistical evi-
dence of an interactive effect of drug with diet regimen
(i.e., LF vs SFA) with drug.
The longer duration of SFA feeding significantly
increased the apo B distribution in the parenchyma (com-
pare y-axis, Figure 1 frame B vs. Figure 3), and this
occurred primarily within the HPF. The efficacy of a
longer period of intervention with atorvastatin, pravastatin
or ibuprofen on apo B parenchymal abundance is depicted
in Figure 3 and Figure 4. Provision of atorvastatin, pravas-
tatin and also ibuprofen for 8 weeks completely sup-
pressed the SFA-induced effect (Figure 3). This marked
improvement with all three agents included normalisation
of the HPF accumulation of apo B lipoproteins. There was
no evidence of an interactive effect of drugs with diet.
The SFA diet was generally well tolerated consistent
with no significant changes in plasma total cholesterol
or triglyceride compared to LF controls (Tables 1 and 2).
Indeed, the LF control had modestly higher plasma tri-
glyceride compared to other intervention groups.
Weight gain was also similar between all treatment
groups relative to duration of experimental design (data
not shown). Some differential agent effects were
observed. Mice randomised to LF with atorvastatin (LF
+ At) diet for 8 weeks had significantly lower plasma
cholesterol, triglyceride and non-esterified fatty acids
(NEFA) concentrations (vs. LF control, Table 2), but this
was not observed with the provision of atorvastatin withthe SFA diet. Ibuprofen and pravastatin had no substan-
tial effects on plasma lipid or NEFA concentrations.
Pearson’s correlation analysis found no association
between plasma lipid homeostasis and the parenchymal
abundance or distribution of IgG or apo B for any of the
interventions described (data not shown).
Discussion
We confirm that SFA feeding significantly disrupts BBB
integrity and function [35], resulting in exaggerated
Figure 2 3-D immunofluorescent staining of cerebral IgG in
mice randomised to diet + drug for 2 weeks. Parenchymal
leakage of IgG (green) is observed surrounding the cerebral
microvessels. Nuclei are shown in blue. The 3D images are from
mice fed low-fat (LF), saturated-fatty acids (SFA) and SFA mice
randomised to drug diets containing atorvastatin (LF + At, SFA + At),
pravastatin (LF + Pr, SFA + Pr) and ibuprofen (LF + Ib, SFA + Ib) for
2 weeks. Scale: 1 unit = 42.7 μm.
Pallebage-Gamarallage et al. Lipids in Health and Disease 2012, 11:117 Page 4 of 10
http://www.lipidworld.com/content/11/1/117cerebral extravasation of IgG and apo B, but now extend
those findings and show an association of severity of dys-
function with duration of SFA feeding. Immunoglobulin-
G and apo B lipoproteins are derived from peripheral cir-
culation with molecular weights of approximately 166 kDa
and 2.2-20 × 106 kDa, respectively, and are commonly
used as a surrogate markers for BBB permeability. The
measurement of cerebral abundance of different molecular
weight proteins approximates the extent of vascular per-
meability in cerebral tissue [36]. Wild-type mice fed a SFA
diet for 12 weeks had a 5-fold increase in parenchymal
abundance of IgG compared to the LF control and about a
2-fold increase in apo B abundance. However, 20 weeks of
SFA consumption resulted in >3-fold increase in cerebral
apo B abundance when compared to the LF control.Figure 3 Quantitation of cerebral apo B in mice randomised to
diet + drug for 8 weeks. The bar graphs show 3-dimensional (3D)
quantitative analysis of apo B leakage of wild-type mouse brains.
Pixel intensity of apo B was quantitated surrounding the
cerebrovasculature in mice fed low-fat (LF), saturated-fatty acids
(SFA) and SFA mice randomised to diets containing atorvastatin (LF
+ At, SFA + At), pravastatin (LF + Pr, SFA + Pr) and ibuprofen (LF + Ib,
SFA + Ib). Apo B pixel intensity was measured in the cortex (CTX,
black column), brain-stem (BS, white column) and hippocampal
formation (HPF, dotted column) and expressed as per unit volume.
Symbol→ indicate that mice were fed SFA diet for 12 weeks and
then the diet was replaced (→) with a drug containing diet.The bars
represent mean intensity and standard error of mean, where P < 0.05
considered statistically significant. a: statistically significant in
comparison to LF. b: statistically significant in comparison to SFA.
Figure 4 3-D immunofluorescent staining of cerebral apo B in
mice randomised to diet + drug for 8 weeks. Parenchymal
leakage of apo B (red) is observed surrounding the cerebral
microvessels. Nuclei are shown in blue. The 3D images are from
mice fed low-fat (LF), saturated-fatty acids (SFA) and SFA mice
randomised to drug diets containing atorvastatin (LF + At, SFA + At),
pravastatin (LF + Pr, SFA + Pr) and ibuprofen (LF + Ib, SFA + Ib) for
8 weeks. Scale: 1 unit = 42.7 μm.
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ation of SFA feeding, the greater degree of vascular
permeability.
The protective role of statins and NSAIDs on dietary-
induced vascular disorders suggests properties that may
attenuate cerebral capillary dysfunction [37,38]. The
objective of this study was to assess whether dietary SFA-
induced cerebral extravasation of IgG and apo B could be
reversed by atorvastatin, pravastatin, or ibuprofen in WT
mice. A key finding was that atorvastatin completely abol-
ished the accumulation of brain parenchymal IgG and apo
B within 8 weeks of treatment and that restoration of
function had commenced within just 2 weeks of treat-
ment. This atorvastatin-induced reversal phenomenon oc-
curred independent of whether the mice were maintained
on the LF or SFA diet, suggesting potent effects in the
continued presence of a potent dietary vascular insult.
Similarly, ibuprofen had regressed cerebral abundance of
IgG at 2 weeks of intervention, however the magnitude of
its effects were not as profound as atorvastatin. A part
systemic-mediated phenomenon is supported by the find-
ing that pravastatin, a water soluble statin with poor diffu-
sion properties through the BBB showed efficacy, albeit at
8 weeks of treatment. Atorvastatin, being lipophilic, can
passively diffuse through the BBB allowing more rapid and
widespread tissue distribution [39]. Pravastatin requires a
rate limiting active transport system for cerebral delivery
to occur [39].
Evidence that the beneficial effects of atorvastatin and
pravastatin on BBB integrity and function were mediated
via regulation of inflammation and not lipid metabolism
are suggested by the findings with ibuprofen, a non-
selective COX inhibitor. Parenchymal abundance of IgG
was substantially reduced following 2 weeks of treatment
in mice that had been fed an SFA-enriched diet for
12 weeks. Apo B abundance was also significantly
reduced with ibuprofen therapy after 8 weeks, analogous
to the findings with atorvastatin.
Regional differences in statin or ibuprofen-induced
restoration were observed. Atorvastatin was most effect-
ive in normalising hippocampal IgG load at 2 weeks and
apo B at 8 weeks of intervention, with only partial res-
toration in CTX and BS with longer-term (8 week) treat-
ment. Treatment with pravastatin or ibuprofen, although
less potent than atorvastatin, nonetheless resulted in a
Table 1 Plasma lipid profile of SFA mice randomised to SFA diet + drugs for 2 weeks
SFA 12wk
↓
LF 12wk SFA 12wk LF + At 2wk SFA + At 2wk LF + Pr 2wk SFA + Pr 2wk LF + Ib 2wk SFA + Ib 2wk
Cholesterol (mM) 1.83 ± 0.20 1.54 ± 0.20 1.68 ± 0.11 1.69 ± 0.05 1.64 ± 0.13 1.91 ± 0.13 1.93 ± 0.12 1.59 ± 0.13
Triglycerides (mM) 0.74 ± 0.08 0.34 ± 0.04a 0.39 ± 0.03a 0.34 ± 0.02a 0.36 ± 0.01a 0.40 ± 0.04a 0.42 ± 0.03a 0.31 ± 0.02a
NEFA (mEq/L) 0.85 ± 0.08 0.68 ± 0.04 0.93 ± 0.05 0.82 ± 0.04 1.02 ± 0.05b 0.90 ± 0.08 1.05 ± 0.10b 0.79 ± 0.05
The table shows the effects of various feeding regimens on plasma lipids. Plasma total cholesterol, triglycerides and non-esterified fatty acids (NEFA) were
measured at the end of the feeding regimen. Data represented as mean ± standard error of mean. Means were compared with non-parametric independent t test,
where P < 0.05 considered statistically significant.
a: statistically significant in comparison to LF;
b: statistically significant in comparison to SFA.
Abbreviations: LF, low-fat; SFA, saturated fatty acids; At, atorvastatin; Pr, pravastatin; Ib, ibuprofen; wk, weeks.
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HPF, CTX and BS. Ibuprofen showed evidence of effi-
cacy by 2 weeks in HPF and CTX, but pravastatin had
no significant effect within these regions at 2 weeks. Col-
lectively, these findings indicate that atorvastatin was
most effective in regression of hippocampal plasma pro-
tein abundance independent of duration of intervention.
Longer-term intake of pravastatin and ibuprofen was
required to ameliorate accumulation of plasma proteins
within the HPF.
The HPF is the vital brain region involved in learning,
memory and some suggest, particularly vulnerable to
oxidative damage induced by inflammation [40,41].
Pathological changes reported in human brain speci-
mens indicate that capillary and larger vessel distur-
bances occur within the HPF and precede the structural
abnormalities that then develop within the temporal cor-
tex and other regions of the brain [42-44]. The findings
of previous studies demonstrating the potent effects of
an SFA diet on BBB function principally within the HPF
and of this study, showing the restorative effects of ator-
vastatin are therefore potentially of clinical relevance.
The mechanisms by which atorvastatin, pravastatin
and ibuprofen influenced BBB integrity were not specif-
ically explored in this study. However, the data show
that the improvements in BBB function were not asso-
ciated with plasma lipid homeostasis. These findings
suggest that the diets were well tolerated in our mouseTable 2 Plasma lipid profile of SFA mice switched to diets + d
LF 20wk SFA 20wk LF + At 8wk SFA + A
Cholesterol (mM) 1.64 ± 0.14 1.43 ± 0.08 1.17 ± 0.11a 1.55 ±
Triglycerides (mM) 0.80 ± 0.12 0.55 ± 0.14 0.40 ± 0.04a 0.63 ±
NEFA (mEq/L) 0.70 ± 0.04 0.61 ± 0.07 0.50 ± 0.07a 0.62 ±
The table shows the effects of various feeding regimens on plasma lipids. Plasma to
measured at the end of the feeding regimen. Data represented as mean ± standard
where P < 0.05 considered statistically significant.
a: statistically significant in comparison to LF.
b: statistically significant in comparison to SFA.
Abbreviations: LF, low-fat; SFA, saturated fatty acids; At, atorvastatin; Pr, pravastatinmodel. Consistent with our previous observations where
SFA induced BBB dysfunction was independent of
hypercholesterolemia [35]. Many studies have demon-
strated pleiotropic effects of statins mediated principally
via anti-inflammatory, or suppression of oxidative stress
pathways, including endothelial specific protection
[32,45,46]. In the context of these findings, the statins
were comparable, or in some instances more effective
than the commonly utilised COX inhibitor, ibuprofen.
Similar findings on BBB protection in other models were
reported for atorvastatin in a hypertensive rat model
[32]. They demonstrated that disturbance in BBB perme-
ability improvement with atorvastatin were associated
with abundance of cerebrovascular tight junction pro-
teins; zonula occludens and occludin; plasma nitric oxide
concentration and anti-oxidant homeostasis. Similarly,
pravastatin was shown to reduce micro-vascular perme-
ability and restore vascular endothelial function via
modulation of endothelial nitric oxide synthase level in
micro-vessels of rat mesentery [47].
We previously demonstrated that SFA induced BBB
leakage was associated with significant reduction in the
tight junction protein occludin [35]. Furthermore, stud-
ies have demonstrated increased oxidative stress [48-51]
and inflammatory cytokine [52,53] associated vascular
endothelial dysfunction in rodents maintained on SFA
enriched diets. In the model used in this study, statins
and ibuprofen probably enhanced the expression of tightrug for 8 weeks
SFA 12wk
↓
t 8wk LF + Pr 8wk SFA + Pr 8wk LF + Ib 8wk SFA + Ib 8wk
0.14 1.52 ± 0.17 1.37 ± 0.09 1.81 ± 0.26 1.19 ± 0.11a
0.09 0.89 ± 0.09b 1.00 ± 0.17b 0.57 ± 0.07 0.80 ± 0.14
0.05 0.62 ± 0.06 0.51 ± 0.04a 0.52 ± 0.04a 0.52 ± 0.06a
tal cholesterol, triglycerides and non-esterified fatty acids (NEFA) were
error of mean. Means were compared with non-parametric independent t test,
; Ib, ibuprofen; wk, weeks.
Table 3 Dietary composition
SFA diet LF diet
Calculated nutritional parameters (%)
Protein 13.6 13.6
Total Fat 20.3 4
Crude Fibre 4.7 4.7
Acid Detergent Fibre 4.7 4.7
Total Carbohydrate 50 64.9
Digestible Energy 18.8 MJ/kg 15.1 MJ/kg
% Digestible Energy from Lipids 40 n/a
% Digestible Energy from Protein 15 n/a
Calculated fat composition (%)
Myristic Acid 14:0 0.05 Trace
Pentadecanoic Acid 15:0 0.01 n/a
Palmitic Acid 16:0 5.16 0.2
Megaric Acid 17:0 0.05 n/a
Stearic Acid 18:0 7.31 0.1
Arachidic Acid 20:0 0.24 n/a
Behenic Acid 22:0 0.04 n/a
Tetracosanoic Acid 24:0 0.03 n/a
Palmitoleic Acid 16:1 0.05 Trace
Heptadecenoic Acid 17:1 0.01 n/a
Oleic Acid 18:1 n9 6.62 2.4
Gadoleic Acid 20:1 0.01 n/a
Lenoleic Acid 18:2 n6 0.67 0.8
a Linolenic Acid 18:3 n3 0.05 0.4
g Linolenic Acid 18:3 n6 Not detected n/a
Arachadonic Acid 20:4 n6 Not detected Trace
EPA 20:5 n3 Not detected Trace
DHA 22:6 n3 Not detected Trace
The table shows the total fatty acid composition of SFA and LF. Vitamin and
mineral content were balanced in all diets. The agents were incorporated into
either LF or SFA chow at a concentration of 20 mg/kg (w/w) atorvastatin,
23.4 mg/kg (w/w) pravastatin and 333.3 mg/kg (w/w) ibuprofen.
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repair of this pivotal capillary network.
A paradoxical finding was that abundance of apo B
lipoproteins within brain parenchyme required a longer
duration of treatment with statins or ibuprofen to be
reduced compared IgG, yet apo B lipoproteins have a
molecular weight of up to 100 times greater than IgG.
Notionally, penetrance into brain parenchyme of macro-
molecules such as apo B lipoproteins would become evi-
dent more quickly than large proteins such as IgG.
However, previous findings have shown significant reten-
tion of apo B lipoproteins associated with extracellular
matrices including heparin-sulphate proteoglycans, bigly-
can and decorin [54]. The exaggerated presence of apo B
lipoproteins compared to IgG in SFA mice treated with
statins or ibuprofen, may be indicative of a relatively slow
turnover through brain parenchyma, compared to proteins
that more readily diffuse into cerebrospinal fluid, such as
IgG. Interestingly, apo B lipoproteins that are enriched
with amyloid-beta as a consequence of chronic SFA inges-
tion show remarkable colocalisation with amyloid-plaque
in rodent models of AD [35].
Conclusion
Dysfunction of the BBB is increasingly recognised in
neurodegenerative diseases with cerebral capillary distur-
bances including AD [55]. Although statin and NSAID
use have demonstrated benefits for the prevention of
AD, appropriate treatment following disease develop-
ment is understudied and controversial. The majority of
studies focus on pathological accumulation of Aβ within
the brain parenchyma and neuronal death.
Evidence showing cerebral capillary dysfunction pre-
ceding amyloid deposition is growing. This study pro-
vides novel insight into the effects of atorvastatin,
pravastatin and ibuprofen on regression and prevention
of SFA-induced BBB permeability and preceding amyl-
oidosis. Further studies are required to ascertain the
underlying mechanisms of how statins and ibuprofen
modulate BBB integrity.
Methods
Animals and diet conditions
The Curtin University Animal Experimentation and Eth-
ics Committee approved housing, handling and experi-
mental procedures described for this study. Six-week-old
female WT mice (C57BL/6 J) were housed in groups
and randomised into the diet or drug treatment groups
(6 mice per group). All mice were maintained in a 12 h
light and dark cycle room, at 22°C and with free access
to water and food. Mice were weighed weekly and aver-
age daily diet consumption was recorded.
The LF control group of mice were fed a semi-purified
diet (AIN93M, Glen Forrest Stockfeeders, Glen Forrest,Western Australia) containing 4% (w/w) total fat
(derived from canola oil) and <1% of total digestible en-
ergy from lipids. As previously demonstrated, mice were
fed SFA diet containing 20% (w/w) cocoa butter (SF07-
050, Glen Forrest Stockfeeders) to induce BBB damage
[35]. The SFA diet contained palmitic (16:0) and stearic
(18:0) acids as the primary saturated fats (13% w/w).
Digestible energy for LF and SFA diets were 15.1 MJ/kg
and 18.8 MJ/kg, respectively (Table 3).
To determine the putative restorative effects of ator-
vastatin (At), pravastatin (Pr) and ibuprofen (Ib) on BBB
damage, WT mice were initially fed with SFA diet for a
period of 12 weeks to induce damage to the BBB. The
SFA fed mice were then switched to SFA diets contain-
ing atorvastatin (SFA→ SFA + At), pravastatin (SFA→
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the effect of drugs with insult (SFA diet). Mice switched
to LF diets containing identical doses of atorvastatin
(SFA→ LF + At), pravastatin (SFA→ LF + Pr) or ibupro-
fen (SFA→ LF + Ib) to determine the effects of drugs in
the absence of dietary insult. Animals that were initially
fed SFA diet for 12 weeks were switched to the drug
containing diets (LF + drug or SFA + drug). They were
then sacrificed at two time points, at 2 weeks and
8 weeks after drug intervention, to observe any progres-
sive effects of the drugs on BBB restoration. Mice given
LF or SFA alone were run parallel with all experiments
and sacrificed at each end point.
The agents were incorporated into either LF or SFA
chow at a concentration of 20 mg/kg (w/w) atorvastatin
(Lipitor, Pfizer, Australia), 23.4 mg/kg (w/w) pravastatin
sodium (LipostatW, Australia) and 333.3 mg/kg (w/w) ibu-
profen (I110, Sigma-Aldrich, New South Wales, Australia).
Based on measured consumption rates, the daily ingested
dose for each agent approximated three times the highest
recommended dose for human studies per unit body.
However, the bioavailability of atorvastatin and pravastatin
has been reported to be reduced when consumed with
food [56,57].
Tissue collection and sample preparation
Mice were maintained on the indicated diets and
weighed weekly. Tissue samples were collected as previ-
ously described by Takechi et al. [35]. Mice were
anesthetised with pentobarbitone (45 mg/kg i.p.) and
were exsanguinated by cardiac puncture. Blood was col-
lected into K-2 EDTA tubes and stored on ice. Plasma
was separated by short time, high speed centrifugation
at 4°C and stored at −80°C.
Brain tissues were carefully isolated, washed with
chilled phosphate buffered saline (PBS, pH 7.4), and the
right hemispheres were separated and fixed in 4% paraf-
ormaldehyde for 24 h. The tissues were then cryopro-
tected with 20% sucrose solution at 4°C for 72 h, frozen
in isopentane with dry ice and stored at −80°C. For hist-
ology and fluorescence microscopy, serial cryo-sections
of 18 μm were cut from the right cerebral hemispheres
for each mouse and mounted on Polysine slides [35].
Immunoglobulin-G and apolipoprotein B
immunofluorescence
Cerebrovascular leakage of IgG and apo B were detected
as previously described [35]. Brain cryosections (18 μm)
were air-dried for 30 min, rehydrated with PBS and
incubated in blocking serum (10% goat serum) prior to
application of the antibodies.
For IgG staining, tissues were incubated with goat
anti-mouse IgG-Alexa 488 flurochrome conjugated anti-
body (Invitrogen) at 1:100 dilution, overnight at 4°C.The sections were then washed with PBS and nuclei
were counterstained with DAPI (1:1000) for 5 min at
room temperature. Thereafter, the stained sections were
mounted with anti-fade mounting medium.
Cerebral apo B was detected by overnight incubation
with polyclonal rabbit anti-apo B as the primary anti-
body (ab20737, Abcam, Cambridge, UK) at 1:500 dilu-
tion, at 4°C. Post-overnight incubation, primary antibody
was labelled at room temperature with the secondary
goat anti-rabbit IgG-Alexa 488 conjugate (Invitrogen)
for 2 h. The tissues were then counterstained with DAPI
and mounted as per IgG staining method [35].
Immunofluorescent imaging of and quantitative analysis
of cerebral IgG and apo B
Digital images for photomicroscopy were acquired
through AxioCam HRm camera (Zeiss Germany) with an
AxioVert 200 M inverted microscope by Zeiss (Germany)
at × 200 magnification (Plan Neofluar x20 objective, 1.3
numerical aperture). Three-dimensional (3-D) images
were captured through ApoTome optical sectioning meth-
odology (Carl Zeiss) [35,58]. Each 3-D image consisted of
6–10 two-dimensional images and the distance between
Z-stack slices was 1·225 μm optimised by Nyquist. A mini-
mum of nine 3-D images were randomly captured per
mouse, which include 5 images within the CTX and 2
images each from BS and HPF.
Cerebrovascular leakage of plasma proteins IgG and apo
B were quantified within the CTX, BS and HPF. The pixel
intensity of protein of interest surrounding the blood ves-
sels for each 3-D image was quantitated utilising the auto-
mated optical intensity measurement tool in Volocity
(Software version 5.5, Perkin Elmer, Melbourne, Australia)
and expressed as per unit volume. The investigator was
blinded during image capturing and quantitative analysis.
Plasma cholesterol, triglyceride and NEFA
Plasma Cholesterol and triglycerides were determined in
duplicate by enzymatic assays (Randox Laboratories
LTD, UK). Non-esterified fatty acids were determined
with NEFA-C (ASC-ACOD method, Wako Pure
Chemical Industries, Osaka, Japan).
Statistical analysis
This study utilised 6 mice per group and minimum of
nine 3-D images were captured per mouse for detection
of IgG and apo B leakage within the CTX, BS and HPF.
In each group, 324–540 two-dimensional images were
generated for adequate statistical comparison.
Normally distributed data were analysed by parametric
one-way analysis of variance to assess the main effects of
the dietary SFA, atorvastatin, pravastatin and ibuprofen
treatment. The Kruskall-Wallis test was utilised if data
was not-normally distributed. Post-hoc comparison of
Pallebage-Gamarallage et al. Lipids in Health and Disease 2012, 11:117 Page 9 of 10
http://www.lipidworld.com/content/11/1/117means was done if the associated main effect or inter-
action was statistically significant within the analysis of
variance procedure. P-values < 0.05 were considered to
be statistically significant.
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